BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 27576566)

  • 1. The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
    Ter Veer E; Haj Mohammad N; van Valkenhoef G; Ngai LL; Mali RMA; Anderegg MC; van Oijen MGH; van Laarhoven HWM
    J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27576566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
    Ter Veer E; Ngai LL; Valkenhoef GV; Mohammad NH; Anderegg MCJ; van Oijen MGH; van Laarhoven HWM
    Sci Rep; 2017 Aug; 7(1):7142. PubMed ID: 28769123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for advanced gastric cancer.
    Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for advanced gastric cancer.
    Wagner AD; Unverzagt S; Grothe W; Kleber G; Grothey A; Haerting J; Fleig WE
    Cochrane Database Syst Rev; 2010 Mar; (3):CD004064. PubMed ID: 20238327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.
    Zhu L; Liu J; Ma S
    Pathol Oncol Res; 2016 Oct; 22(4):853-61. PubMed ID: 27236591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
    Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
    JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry.
    Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Sánchez Cánovas M; Hernández R; Pericay C; Echavarria I; Lacalle A; Visa L; Rodríguez Palomo A; Mangas M; Cano JM; Buxo E; Álvarez-Manceñido F; García T; Lorenzo JE; Ferrer-Cardona M; Viudez A; Azkarate A; Ramchandani A; Arias D; Longo F; López C; Sánchez Bayona R; Limón ML; Díaz-Serrano A; Fernández Montes A; Sala P; Cerdá P; Rivera F; Gallego J;
    Gastric Cancer; 2018 Jan; 21(1):96-105. PubMed ID: 28393278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.
    Wang C; Song DJ; Xu ZL; Xie SP; Hu JH
    Exp Mol Med; 2017 Sep; 49(9):e383. PubMed ID: 28960212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress in chemotherapy for advanced gastric cancer].
    Xu RH; Teng KY
    Ai Zheng; 2009 Oct; 28(10):1108-13. PubMed ID: 19799823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone.
    Hamada C; Yamada Y; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hyodo I
    Int J Clin Oncol; 2016 Aug; 21(4):668-675. PubMed ID: 26733020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D; Starling N; Rao S; Iveson T; Nicolson M; Coxon F; Middleton G; Daniel F; Oates J; Norman AR;
    N Engl J Med; 2008 Jan; 358(1):36-46. PubMed ID: 18172173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The choice of treatment in advanced gastric cancer].
    Pozzo C; Mansueto G
    Tumori; 2007; 93(6):suppl 11-21. PubMed ID: 18338512
    [No Abstract]   [Full Text] [Related]  

  • 14. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
    Starling N; Rao S; Cunningham D; Iveson T; Nicolson M; Coxon F; Middleton G; Daniel F; Oates J; Norman AR
    J Clin Oncol; 2009 Aug; 27(23):3786-93. PubMed ID: 19398575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
    Shitara K; Kadowaki S; Nishina T; Sakai D; Yoshikawa R; Piao Y; Ozeki A; Inoue K; Gritli I; Muro K
    Gastric Cancer; 2018 Jan; 21(1):106-113. PubMed ID: 28667466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
    Ajani JA; Buyse M; Lichinitser M; Gorbunova V; Bodoky G; Douillard JY; Cascinu S; Heinemann V; Zaucha R; Carrato A; Ferry D; Moiseyenko V
    Eur J Cancer; 2013 Nov; 49(17):3616-24. PubMed ID: 23899532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
    Pozzo C; Barone C
    Oncologist; 2008 Jul; 13(7):794-806. PubMed ID: 18614586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.